Skip to content

Compare methods

Compare source explanations, strengths, limitations and references for up to four methods.

7 results
Criterion Skindex-29 POEM
Overview
  • Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.
  • The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.
Use and interpretation
  • Skindex-29 is appropriate for any patient with a skin disease, regardless of severity or clinical type. It is particularly valuable in trials of conditions with high quality-of-life burden (acne, atopic dermatitis, psoriasis, alopecia, vitiligo, ichthyosis) to ensure treatment efficacy encompasses not only clinical improvement but emotional and functional benefit. Skindex-29 is also used in observational studies to quantify disease burden in specific populations and to identify patients at high risk of depression or social isolation. In clinical practice, periodic Skindex-29 assessment (baseline, 8–12 weeks, 6 months) helps identify patients whose quality of life is not improving despite objective clinical progress and may indicate need for psychological support or therapy adjustment.
  • POEM is ideal for longitudinal monitoring in both clinical practice and trials, particularly when frequent assessment is needed (weekly or bi-weekly). It is especially useful for telemedicine visits, home-based monitoring, and populations unable to attend in-person clinician assessments. POEM complements objective measures; in modern trials, POEM and an objective measure (EASI or SCORAD) are often used together. For pure severity grading at a single timepoint, a clinician-rated measure may be preferred, but POEM is superior for tracking change and capturing patient experience.
Strengths
  • Patient-centered; directly captures impact on emotions, functioning, and daily symptoms rather than clinical signs.
  • Multidimensional; three subscales enable nuanced understanding of which QoL domains are most affected.
  • Broadly applicable; validated across all major skin diseases (eczema, psoriasis, acne, alopecia, vitiligo) and diverse populations.
  • Responsive to treatment; sensitive to clinically meaningful change with both topical and systemic therapies.
  • Practical; brief (29 items, 5–10 minutes) self-administered format suitable for routine clinical use and trials.
  • Validated translations available in 15+ languages.
  • Strong psychometric properties: internal consistency, test-retest reliability, construct validity.
  • Emotional subscale particularly sensitive in conditions with psychological burden (acne, alopecia).
  • Patient-administered; no clinician expertise or training required, enabling use in any setting (primary care, telemedicine, home).
  • Practical and brief; completion takes 2–3 minutes; low respondent burden increases compliance.
  • Validated from age 2 years upward; reliable in both children and adults.
  • Responsive to treatment change; sensitive to clinically meaningful improvement.
  • Captures patient-centered outcomes; frequency of itching and sleep loss align with quality-of-life impact.
  • Suitable for frequent assessment; symptom frequency over past 7 days enables weekly tracking.
  • Strong internal consistency and test-retest reliability in diverse populations.
Limitations
  • Subjective recall; patients' memory of QoL impact over the past month may vary with current mood or recent events.
  • No clinician-rated version; cannot be completed by proxy (unlike DLQI variants for young children).
  • Ceiling effects possible in very mild disease; patients with minimal QoL impact may score near zero across all items.
  • Does not capture objective disease severity; a patient with severe psoriasis but high coping may score lower than a patient with mild disease and high distress.
  • Symptom items focus on subjective perception (itching, burning) rather than objective clinical signs; does not replace clinical assessment.
  • Recall period of 'past month' is fixed; adaptation for different assessment intervals is not formally validated.
  • Subjective recall; patients may not accurately remember symptom frequency over a 7-day period, especially for mild symptoms.
  • Does not capture clinician-observable signs (extent, lichenification, induration); purely symptom-based.
  • Ceiling effects possible in very severe disease; differentiation between 'every day' responses is limited.
  • Culturally sensitive interpretation of terms (e.g., 'oozing') may vary; translations require validation.
  • Sleep loss item may conflate atopic dermatitis with other sleep disruptions (stress, comorbid sleep disorders).
  • Not suitable for very young children (<2 years); parental proxy rating may underestimate infant symptoms.
Common pitfalls
  • Interpreting high Skindex-29 scores as indication that clinical treatment has failed; high QoL burden may reflect long-standing disease, poor adjustment, or comorbid mental health conditions. Psychological support or referral to psychiatry may be appropriate in addition to dermatological treatment.
  • Using only Skindex-29 without objective severity measures (PASI, EASI, SCORAD); regulatory agencies require both clinical efficacy and QoL outcomes, so always use together.
  • Assuming all three subscales are equally important for all conditions; in acne, the Emotions subscale is typically most affected; in psoriasis, Functioning may dominate. Report all three and highlight the most impacted domain.
  • Failing to administer Skindex-29 at multiple timepoints; a single timepoint does not establish treatment responsiveness. Measure at baseline, 8–12 weeks, and final visit minimum.
  • Misinterpreting scale direction; remember that HIGHER Skindex-29 scores = WORSE QoL (not better). Do not confuse with other scales where higher = improvement.
  • Using POEM as the sole severity measure in clinical trials; objective assessment (EASI or SCORAD) should always accompany POEM to capture clinician-observable disease extent and sign intensity.
  • Interpreting POEM scores in isolation without understanding the underlying symptoms; a POEM of 8 (mild-moderate) with predominant itching is clinically different from a POEM of 8 with predominant oozing.
  • Assuming POEM is interchangeable with SCORAD or EASI; POEM measures symptom frequency, not sign intensity or body surface area involvement, and does not directly correlate with objective measures.
  • Failing to assess adherence or understanding; patients may misinterpret 'days' (calendar days vs. nights vs. any symptom during the day).
  • Using POEM in infants under 2 years with parental proxy rating without validating the parent's understanding of each symptom.
Introduced by
  • Chren MM, Lasek RJ
  • Charman CR, Venn AJ, Williams HC
Year
  • 1997
  • 2004